Maxygen Appoints Louis G. Lange to Its Board of Directors
December 09 2005 - 4:00PM
PR Newswire (US)
REDWOOD CITY, Calif., Dec. 9 /PRNewswire-FirstCall/ -- Maxygen,
Inc. (NASDAQ:MAXY) today announced the appointment of Louis G.
Lange, M.D., Ph.D. to its Board of Directors. Dr. Lange is a
founder of CV Therapeutics (NASDAQ:CVTX) and has served as chairman
of the board and chief executive officer of the company since
August 1992. From 1980 to 1992, Dr. Lange served on the faculty of
Washington University School of Medicine, including as Chief of
Cardiology at Jewish Hospital in St. Louis, Missouri from 1985 to
1992, and as a full Professor of Medicine from 1990 until 1992. Dr.
Lange holds an M.D. from Harvard Medical School and a Ph.D. in
biological chemistry from Harvard University. "Lou is a welcome
addition to our Board," said Russell Howard, chief executive
officer of Maxygen. "As Maxygen's products move into clinical
development and towards commercialization, we believe Lou's
leadership, experience and strategic insights will contribute
substantially to the Maxygen Board." "I am pleased to join
Maxygen's board of directors," said Dr. Lange. "Maxygen is at an
exciting point in its corporate development with several promising
products and I look forward to being a part of this talented team
of scientific and business people." About Maxygen Maxygen, Inc.,
headquartered in Redwood City, California, is focused on creating
novel products using its integrated proprietary technologies for
human therapeutics. Maxygen's technologies bring together advances
in molecular biology and protein modification to create novel
biotechnology products. DATASOURCE: Maxygen, Inc. CONTACT: Jeannine
Medeiros, Investor and Public Relations of Maxygen, Inc.,
+1-650-298-5853, or Web site: http://www.maxygen.com/
Copyright
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Sep 2024 to Oct 2024
CV Therapeutics (NASDAQ:CVTX)
Historical Stock Chart
From Oct 2023 to Oct 2024